Momecutan (Mometasone Furoate Ph. Eur.)

Mometasone furoate penetrates the skin and binds to intracellular glucocorticoid receptors. The drug‑receptor complex alters gene transcription, suppressing pro‑inflammatory cytokines, inhibiting leukocyte migration, and reducing vasodilation. This results in potent anti‑inflammatory and immunosuppressive effects at the site of application.

The appropriate dose of Momecutan is determined by the prescribing healthcare professional based on the specific condition, severity, patient age and the area of skin to be treated. Patients should follow the prescriber’s instructions and not exceed the recommended amount.

Safety of topical mometasone furoate during pregnancy or lactation has not been fully established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Momecutan.

To request Momecutan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and import documentation.

Momecutan (mometasone furoate) is a high‑potency corticosteroid, offering stronger anti‑inflammatory activity than low‑potency agents such as hydrocortisone, but it is less potent than very high‑potency steroids like clobetasol propionate. This balance makes it suitable for moderate to severe dermatitis while limiting systemic exposure when used as directed.

Momecutan should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperatures to maintain its stability and efficacy.

Momecutan is applied topically to the affected skin area. The prescribed amount is gently spread in a thin layer, usually once or twice daily, and gently rubbed in until fully absorbed. Hands should be washed before and after application, and the treated area should not be covered with occlusive dressings unless advised.

Serious risks include skin atrophy, secondary infections, systemic adrenal suppression with extensive use, and hypersensitivity reactions such as urticaria or angioedema. Patients should report any unusual skin changes, signs of infection or systemic symptoms to their healthcare provider promptly.

Momecutan should be avoided in individuals with known hypersensitivity to mometasone furoate or any formulation components, in patients with untreated bacterial, viral or fungal skin infections, and in those where systemic corticosteroid therapy is contraindicated. A healthcare professional should evaluate suitability before initiating therapy.